• Login
    View Item 
    •   DSpace Home
    • A) Producción científica UCSC
    • Artículos Científicos
    • View Item
    •   DSpace Home
    • A) Producción científica UCSC
    • Artículos Científicos
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Productivity changes of pharmaceutical industry in Bangladesh: Does process patent matter?

    Thumbnail
    View/Open
    Productivity Changes of Pharmaceutical Industry in Bangladesh Does Process Patent Matter.pdf (498.0Kb)
    Date
    2018-08
    Author
    Azad, Abul Kalam
    Munisamy, Susila
    Teng, Kwek Kian
    Talib, Muzalwana Binti Abdul
    Saona, Paolo
    Publisher
    SAGE
    Description
    Artículo de publicación SCOPUS
    Metadata
    Show full item record
    Abstract
    The large pharmaceutical companies in Bangladesh have currently expertise in process patent activities rather than in product patent. Such industry condition can easily generate a high profile in production and sales. However, achieving sustainability in the long run using automation and purchase of the patent only seems unsuitable. In the last two decades, it is found that both the medium and big size companies have leaned on introducing automation in their existing product plants, improving them in nothing but production. The article measures technical efficiency using data envelopment analysis (DEA) over the period of 2009–2013. We use one output—annual sales—and three inputs, namely, (a) fixed asset, (b) raw material cost and (c) cost of salary to run Malmquist total factor productivity (TFP) index. The major contributor of TFP growth is found due to the technological positive growth with a value of 10.8 per cent annually. Moreover, all changes of technical efficiency, pure efficiency and scale efficiency have regressed with values of 5.5 per cent, 2.1 per cent and 3.5 per cent, respectively. Thus, the gains in productivity are entirely due to technological advancements and not for technical improvements. The main source of inefficiency in pharmaceutical industry is scale inefficiency rather than pure technical inefficiency. Limitations and policy implications are addressed.
    URI
    http://repositoriodigital.ucsc.cl/handle/25022009/2062
    Ir a texto completo en URI:
    https://doi.org/10.1177/0972150918772966
    Collections
    • Artículos Científicos

    UCSC
    UCSC | Contact Us | Send Feedback
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    Statistics

    View Usage Statistics

    UCSC
    UCSC | Contact Us | Send Feedback